A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Suvorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- 21 Feb 2018 Planned End Date changed from 1 Sep 2017 to 30 Sep 2018.
- 21 Feb 2018 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2018.
- 26 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.